Dana Goldman and Anupam Jena write in The Washington Post that the Trump administration may succeed in lowering drug prices by fostering competition and innovation, and possibly ending kickbacks in the supply chain.
Pharmaceutical Pricing and Medical Innovation
Other featured articles
Generic Drug Price Hikes And Out-Of-Pocket Spending For Medicare Beneficiaries
The share of generic drugs that at least doubled in price increased fourfold according to the Health Affairs study. But, this share is still a small percentage of the generic market.
Do Price Spikes on Some Generic Drugs Indicate Problems in the Generics Market?
Despite the overall success of the generic drug market, sudden price hikes are becoming more common according to new Schaeffer Center study
When We Find a Cure, Price it Like Netflix to Ensure Access
Dana Goldman and his colleagues have shown that such subscription models can improve outcomes and save money at the same time.
An Economist’s Change of Heart: It’s Time to Regulate the Prescription- Drug Middlemen
Pharmacy-benefit managers find ways to boost their bottom line at the expense of employers and patients, writes Geoffrey Joyce in Market Watch.
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.